Literature DB >> 2419414

Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.

M L Shin, G Hänsch, V W Hu, A Nicholson-Weller.   

Abstract

Species-restricted lysis of complement refers to the relative inefficiency of complement to lyse cells from the homologous species. Restriction occurs at least at the steps involving C3/C5 convertase formation and the C9 insertion phase of the complement cascade, and is presumed to be mediated by inhibitory factors in the target cell membrane. In this study, we have examined whether decay accelerating factor (DAF), a membrane protein known to modulate C3/C5 convertase activities on cell surfaces, acts as a regulatory protein in species-restricted lysis of human erythrocyte (E). The role of DAF was assessed in homologous lysis by the classic pathway, in reactive lysis, and in lytic steps requiring C8 and C9. The results indicated that DAF participated in regulating C3/C5 deposition on the surface of homologous E, but had no effect on homologous restriction in reactive lysis and in the reaction of C8 and C9 with antibody-sensitized E C1-7. Treatment of E with pronase or with dithiothreitol (DTT) abolished the restricting effect of homologous C8/C9, indicating that species-restricted lysis by C5b-9 involves membrane factor(s) sensitive to pronase and DTT.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2419414

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody.

Authors:  D R Wren; M Noble
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

2.  Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55.

Authors:  Bing Li; Daniel J Allendorf; Richard Hansen; Jose Marroquin; Daniel E Cramer; Claire L Harris; Jun Yan
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

3.  Monoclonal antibody-mediated cytotoxicity against rat beta cells detected in vitro does not cause beta-cell destruction in vivo.

Authors:  B Ziegler; S Lucke; E Köhler; B Hehmke; M Schlosser; S Witt; W Besch; M Ziegler
Journal:  Diabetologia       Date:  1992-07       Impact factor: 10.122

4.  C8 binding protein bears I antigenic determinants.

Authors:  P Blaas-Mautner; S Filsinger; B Berger; D Roelcke; G M Hänsch
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

5.  Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.

Authors:  L S Zalman; L M Wood; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

Review 6.  [Paroxysmal nocturnal hemoglobinuria].

Authors:  P Blaas; S Weber; G M Hänsch; H H Peter
Journal:  Klin Wochenschr       Date:  1990-03-05

7.  Synthesis of aberrant decay-accelerating factor proteins by affected paroxysmal nocturnal hemoglobinuria leukocytes.

Authors:  D J Carothers; S V Hazra; S W Andreson; M E Medof
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

8.  Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.

Authors:  Antonio M Risitano; Bruno Rotoli
Journal:  Biologics       Date:  2008-06

9.  Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9.

Authors:  G M Hänsch; S Schönermark; D Roelcke
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

Review 10.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.